



## RESEARCH ARTICLE

# SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signaling

Liang Xu<sup>1</sup>, Peixue Li<sup>1</sup>, Xue Hao<sup>1</sup>, Yi Lu<sup>1</sup>, Mingxian Liu<sup>1</sup>, Wenqian Song<sup>1</sup>, Lin Shan<sup>1</sup>, Jiao Yu<sup>1</sup>, Hongyu Ding<sup>1</sup>, Shishuang Chen<sup>1</sup>, Ailing Yang<sup>1</sup>, Yi Ariel Zeng<sup>1</sup>, Lei Zhang<sup>1,2,3</sup>✉, Hai Jiang<sup>1</sup>

<sup>1</sup> State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China

<sup>2</sup> School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China

<sup>3</sup> Bio-Research Innovation Center, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Suzhou 215121, China

✉ Correspondence: rayzhang@sibcb.ac.cn (L. Zhang), hai@sibcb.ac.cn (H. Jiang)

Received December 30, 2019 Accepted May 11, 2020

## ABSTRACT

Dysfunction of the Hippo pathway enables cells to evade contact inhibition and provides advantages for cancerous overgrowth. However, for a significant portion of human cancer, how Hippo signaling is perturbed remains unknown. To answer this question, we performed a genome-wide screening for genes that affect the Hippo pathway in *Drosophila* and cross-referenced the hit genes with human cancer genome. In our screen, *Prosap* was identified as a novel regulator of the Hippo pathway that potently affects tissue growth. Interestingly, a mammalian homolog of *Prosap*, SHANK2, is the most frequently amplified gene on 11q13, a major tumor amplicon in human cancer. Gene amplification profile in this 11q13 amplicon clearly indicates selective pressure for SHANK2 amplification. More importantly, across the human cancer genome, SHANK2 is the most frequently amplified gene that is not located within the *Myc* amplicon. Further studies in multiple human cell lines confirmed that SHANK2 overexpression causes deregulation of Hippo signaling through competitive binding for a LATS1 activator, and as a potential oncogene, SHANK2 promotes cellular transformation and tumor formation *in vivo*. In cancer cell lines with deregulated

Hippo pathway, depletion of SHANK2 restores Hippo signaling and ceases cellular proliferation. Taken together, these results suggest that SHANK2 is an evolutionarily conserved Hippo pathway regulator, commonly amplified in human cancer and potently promotes cancer. Our study for the first time illustrated oncogenic function of SHANK2, one of the most frequently amplified gene in human cancer. Furthermore, given that in normal adult tissues, SHANK2's expression is largely restricted to the nervous system, SHANK2 may represent an interesting target for anticancer therapy.

**KEYWORDS** SHANK2, oncogene, Hippo signaling, cancer

## INTRODUCTION

In order to prevent malignant outgrowth, the number of cells in organs and tissues is tightly regulated. For normal cells in monolayer culture or in a tissue, proliferation is usually halted when cells reach high density (Gumbiner and Kim, 2014). As cell density increases, gradual changes in the cellular microenvironment, including cell-ECM and cell-cell interactions, cell shape and tension will impact cellular proliferation (Halder et al., 2012). Such a mechanism of “contact inhibition” is important for tissue homeostasis, and loss of contact inhibition is a hallmark of human cancer (Hanahan and Weinberg, 2011; Yu et al., 2015).

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s13238-020-00742-6>) contains supplementary material, which is available to authorized users.


The Hippo signaling pathway is a primary responder for contact inhibition (Hanahan and Weinberg, 2011; Halder et al., 2012; Yu et al., 2015). First discovered in *Drosophila*, the Hippo pathway has been shown to significantly affect cell number and tissue growth (Harvey et al., 2003; Jia et al., 2003; Pantalacci et al., 2003; Udan et al., 2003; Wu et al., 2003; Huang et al., 2005). Later studies in mammalian system reached similar conclusions and showed that deregulation of the Hippo pathway causes cancer (Zender et al., 2006; Dong et al., 2007; Zhou et al., 2009; Atkins et al., 2016). The core components of Hippo pathway consist of upstream kinases MST1/2 and LATS1/2, which are activated by various upstream signals (Dupont et al., 2011; Wehr et al., 2013; Wang et al., 2015; Yang et al., 2015; Chakraborty et al., 2017) including cell-cell contact, and the downstream transcription cofactors YAP and TAZ, which promote cellular proliferation (Siew et al., 2008; Zhao et al., 2010; Halder and Johnson, 2011). Phosphorylation of YAP/TAZ by LATS1/2 leads to cytoplasmic sequestration and degradation of these transcription cofactors, thereby stopping cell growth and proliferation (Liu et al., 2010; Zhao et al., 2010).


Escaping from contact inhibition provides advantages for cancer cells, and facilitates tumorigenesis (Hanahan and Weinberg, 2011). However, analysis of human cancer genomes suggests that abnormalities of core components of the Hippo pathway, including mutations involving GNAQ (Yu et al., 2012; Feng et al., 2014), GNA11 (Yu et al., 2012, 2014) and NF2 (Xiao et al., 2003; Zhang et al., 2010; Yin et al., 2013), deletions involving VGLL4 (Jiao et al., 2014; Zhang et al., 2014), MST1 (Zhou et al., 2009; Song et al., 2010) and LATS1 (Yu et al., 2013), as well as amplifications involving YAP and TAZ (Overholtzer et al., 2006; Zender et al., 2006; Fernandez-L et al., 2009; Song et al., 2014), occur in a relatively small fraction of human cancer (Sanchez-Vega et al., 2018). Epigenetic silencing of MST1/2 and LATS1/2 has also been observed in mesothelioma (Maille et al., 2019) and sarcomas (Seidel et al., 2007; Merritt et al., 2018), as well as lung (Malik et al., 2018) and colorectal cancer (Wierzbicki et al., 2013). It remains unclear whether deregulation of other unknown components of the Hippo pathway may occur in human cancer and contribute to cancer growth.

In order to answer this question, we performed a genome-wide overexpression screen for novel Hippo pathway regulators in *Drosophila* and cross-referenced the screen hits with human cancer genome data to identify potential oncogenes with a role in Hippo signaling. Our results suggest SHANK2 is such an evolutionarily conserved regulator of Hippo pathway, commonly amplified in human cancer and potently promotes tumor formation.

### Figure 1. *Prosap* overexpression causes tissue overgrowth via deregulation of the Hippo pathway in *Drosophila*.

(A) The location of p-element insertion in *Prosap EP-1* (A569) and *Prosap EP-2* (A723) fly lines in chromosome. In both cases, insertions are located at 1,518 base pair upstream of the *Prosap* start codon. The inserted sequences in these two lines are different. (B) Eye overgrowth phenotype caused by *yki* expression was further enhanced by *Prosap EP-1* and *Prosap EP-2*. Shown are representative side views and dorsal views of eyes of indicated genotypes. Expression of *Prosap EP-1*, *Prosap EP-2* and *Yki* in *Drosophila* eyes was driven by *GMR-Gal4*. Scale bars: 100  $\mu$ m. (C) Wing sizes increased in *MS1096* driven *Prosap EP-1* and *Prosap EP-2* lines. Shown are representative images of wings of indicated genotypes. Expression of *Prosap EP-1*, *Prosap EP-2* and *Yki* in *Drosophila* wings was driven by *MS1096-Gal4*. Scale bars: 500  $\mu$ m. In the right panel, data represent mean  $\pm$  SEM from results of three independent experiments;  $n = 13$  for each group.  $P$  value was calculated by Student's  $t$  test;  $***P < 0.001$ . (D) Expression of *Prosap* caused nucleus localization of *Yki*. There are several isoforms encoded by the *Drosophila Prosap* gene. The *Prosap-PA* isoform was used in this study. Shown are representative images of *Drosophila* third-instar larval wing discs. *Prosap* overexpression was achieved in the posterior of wing discs in *hhgal4-Prosap EP-1 Drosophila*. *Ci* (blue) expressed in anterior wing discs was used to show the Anterior/Posterior boundary. The images on the bottom panel showed further magnification of *Yki* and DAPI staining. In posterior wing discs of *hhgal4-Prosap EP-1 Drosophila*, where *Prosap* was overexpressed, *Yki* mainly localized in the nucleus. White dotted lines were used to mark nucleus area stained by DAPI. A, anterior compartment; P, posterior compartment. (E and F) Overexpression of *Prosap* increased *Yki* transcriptional activity. Shown are representative images of *Drosophila* third-instar larval wing discs of indicated genotypes. The transcription level of *Yki* targets *expanded* and *diap1* were analyzed. In the fly strains used in this experiment, the expression of *LacZ* (E) or *GFP* (F) was driven by enhancers of *expanded* or *diap*, respectively. *Prosap* overexpression was achieved by *hhGgal4* promoter in the posterior wing discs of *hhgal4-Prosap EP-1* flies. This led to moderately increased *Yki* activity in the center of posterior wing discs when compared to anterior wing discs. The edge of the posterior wing discs (arrowhead) showed significantly increased *Yki* activity. Scale bars: 100  $\mu$ m. (G) *Wts* regulates tissue growth downstream of *Prosap*. Shown are representative images of wings of indicated genotypes. Expression of *Prosap EP-1* and *Wts* in *Drosophila* wings was driven by *MS1096-Gal4*. *Prosap* overexpression increased wing size, while co-expression of *Wts* suppressed the increase. Scale bars: 500  $\mu$ m. In the lower panel, data represent mean  $\pm$  SEM from results of three independent experiments;  $n = 9$  for each group.  $P$  value was calculated by Student's  $t$  test;  $***P < 0.001$ .





**Figure 2. Hippo signaling and SHANK2 expression in human cell lines.** (A and B) Analysis of human cell lines regarding their functional status of Hippo signaling. Hippo signaling was analyzed in human cell lines at low or high cell density (LD or HD) with indicated antibodies. Western blot analysis was used to analyze YAP phosphorylation status (A), and immunofluorescence was used to analyze subcellular localization of YAP. Scale bars: 10  $\mu$ m (B). (C) Expression level of CTGF and CYR61 in 293T (Hippo-proficient) and Huh1 (Hippo-deficient) cell lines at low or high cell density (LD or HD). The expression level of CTGF and CYR61 was analyzed by qPCR. Data represent mean  $\pm$  SEM from results of three independent experiments. P value was calculated by Student's *t* test; \*\**P* < 0.01, \*\*\*\**P* < 0.0001. (D and E) mRNA and protein level of SHANK2 in indicated human cell lines. For qPCR analysis in (D), data represent mean  $\pm$  SEM from results of three independent experiments. P value was calculated by Student's *t* test; \*\*\*\**P* < 0.0001.

## RESULTS

### Prosap overexpression causes tissue overgrowth via deregulation of Hippo signaling in *Drosophila*

We first searched for novel regulators of Hippo pathway in *Drosophila* using a screening system based on Hippo pathway's regulation of tissue growth. In *Drosophila*, *yki* (ortholog of YAP) overexpression under the control of the *GMR-Gal4* driver (*GMR>yki*) causes an overgrown eye phenotype. This provides a sensitive platform for identifying additional Hippo pathway regulators (Huang et al., 2013; Hu et al., 2016) that may compound or ameliorate such an eye overgrowth phenotype.

To perform the screen, we employed the p-element transposon system (Engels, 1996), which can induce gene overexpression when inserted into the promoter region (Rørth, 1996). We crossed 12,000 p-element inserted flies crossed with *GMR>yki* flies and searched for lines that could enhance the eye overgrowth phenotype induced by *yki* overexpression. Among the fly lines with the most pronounced effect in this screen, two independent *Drosophila* lines, A569 (EP-1) and A723 (EP-2) both exhibited p-element insertion at the 5' UTR region of the *Prosap* gene (Fig. 1A). Both lines showed enhanced eye overgrowth phenotype induced by *yki* overexpression (Fig. 1B). These two lines also showed increased wing size, which is another phenotype associated with deregulated Hippo signaling activity (Fig. 1C) (Hu et al., 2016). Immunostaining experiments confirmed that in these two lines, *Prosap* was overexpressed (Fig. S1A and S1A').

Interestingly, one of *Prosap*'s mammalian homologs, SHANK2, is highly amplified in human cancer. Therefore, we generated transgenic flies that overexpress *Prosap* to further confirm *Prosap*'s ability to promote tissue overgrowth. Consistent with the initial screen results, flies overexpressing *Prosap* caused a moderate eye overgrowth phenotype (Fig. S1B). *Prosap* overexpression also further enhanced the overgrowth phenotype caused by *GMR>yki* (Fig. S1B). In addition, we confirmed that in control flies the endogenous *Prosap* gene was expressed (Fig. S1C and S1D), and RNAi knockdown of *Prosap* caused reduction of wing size (Fig. S1E).

Next, we examined whether *Prosap* regulates Yki. Immunostaining of the imaginal wing discs of *Drosophila* third-instar larvae showed that *Prosap* overexpression

caused Yki nuclear localization (Fig. 1D) and elevated transcriptional level of Yki transcriptional targets *expanded* and *Diap* (Fig. 1E and 1F), confirming that *Prosap* is a novel regulator of Hippo signaling.


Several additional lines of evidence suggest that *Prosap* functions in the Hippo pathway. First, overexpression of *wts* (orthology of LATS) suppressed *Prosap*'s ability to increase wing size (Fig. 1G). The wing size increase and eye overgrowth phenotypes of *Prosap*-overexpressing flies were also suppressed by *yki* RNAi (Fig. 1F and 1G). Lastly, *Prosap* knockdown could not suppress eye overgrowth phenotype induced by *yki* overexpression (Fig. S1B).

Taken together, these results established *Prosap* as a novel regulator of Hippo signaling in *Drosophila* and showed that its overexpression leads to tissue overgrowth.

### Overexpression of SHANK2 deregulates Hippo signaling activity in mammalian cells

In mammals, there are three *Prosap* homologs, SHANK1, SHANK2 and SHANK3 (Naisbitt et al., 1999; Hayashi et al., 2009). Of these three genes, SHANK2 is highly amplified in human cancer. According to TGCA copy number portal (Zack et al., 2013), 11% of human epithelial cancers exhibited focal amplification of SHANK2. In comparison, SHANK1 and SHANK3 are focally amplified each in 2% of human epithelial cancers (Table S1). Therefore we focused on the potential role of SHANK2 as a growth-promoting gene in human cancer.

First, we asked whether similar to its ortholog *Prosap* in *Drosophila*, SHANK2 also affects Hippo signaling in mammalian cells. We first analyzed human cell lines with regards to their Hippo pathway status and SHANK2 expression level. Cell lines are designated as Hippo-proficient if they are able to phosphorylate YAP and sequester YAP in cytoplasm at high cell density (Figs. 2A, 2B, and S2A). In contrast, Hippo-deficient cell lines fail to phosphorylate YAP, and YAP stays in nucleus at high cell density (Figs. 2A, 2B, and S2A). In addition, at high cell density, YAP transcription activities are low in Hippo-proficient cell lines and high in Hippo-deficient cell lines (Figs. 2C and S2B). Consistent with the finding that *Prosap* deregulates Hippo signaling in *Drosophila*, in two Hippo-proficient cell lines SHANK2 is not expressed, whereas in Hippo-deficient human cell lines SHANK2 is highly expressed (Fig. 2D and 2E).



◀ **Figure 3. SHANK2 deregulates Hippo pathway, transforms primary cells and promotes tumor growth.** (A) Ectopic expression of SHANK2 reduced YAP phosphorylation at high cell density in 293T cells. (B) In Hippo-proficient cell line 293T, ectopic expression of SHANK2 caused YAP to remain in nucleus at high cell density. Scale bars: 10  $\mu$ m. (C) Expression of SHANK2 transformed 293T cells and enabled growth on soft agar. Lower panel, data represent mean  $\pm$  SEM from results of three independent experiments. *P* value was calculated by Student's *t* test; \*\*\**P* < 0.001. (D and E) Expression of SHANK2 promoted tumor growth in nude mice. 2 million of 293T cells expressing vector control or exogenous SHANK2 were transplanted into nude mice (*n* = 7) (D). 2 million of Comma-D $\beta$  mouse mammary cells expressing vector control or exogenous SHANK2 were transplanted into the fat pad of breast of nude mice (*n* = 8) (E). Measurement of tumor growth started after 12 days (D) or 27 days (E) post injection. Data present mean  $\pm$  SEM. *P* value was calculated by Student's *t* test; \*\**P* < 0.01, \**P* < 0.05. (F and F'') Expression of SHANK2 promoted liver tumor formation in the context of Myc and p53 mutation. Liver tumors were induced in mice by hydrodynamically injecting the transposon vector control or exogenous SHANK2 combined with p53R246S and Myc. p53R246S is the murine version of p53R249S, a hotspot mutation commonly observed in human liver cancer. Shown are images of mice liver tumors (F), the statistics of tumor number (*n* = 3) (F') and the expression level of YAP transcriptional target genes CTGF and CYR61 in tumors (F''). Data represent mean  $\pm$  SEM. *P* value was calculated by Student's *t* test; \*\*\**P* < 0.001, \*\*\**P* < 0.001. (G) Correlation of SHANK2 and CTGF, CYR61 expression in uterine corpus endometrial carcinoma (UCEC). The TCGA UCEC datasets were used for this analysis. Correlations between CTGF, CYR61 with YAP and two established positive regulators of YAP (WBP2 and STK26) were also shown in comparison.

Next, we asked whether SHANK2 deregulates mammalian Hippo signaling and promotes cell growth. Ectopic expression of SHANK2 in Hippo-proficient cells suppressed YAP phosphorylation at high cell density (Fig. 3A). SHANK2 expression also caused YAP nuclear retention and high YAP activity despite high cell density (Figs. 3B, S3A, and S3B). This suggests that SHANK2 overexpression leads to deregulation of Hippo signaling in mammalian cells.

### SHANK2 potently promotes tumor growth


Next, we asked whether it functions as an oncogene to promote cancer. We first tested SHANK2's ability to transform cells. In 293T cells, tumor suppressors Rb1 and p53 are inactivated by the SV40 large T antigen (Stepanenko and Dmitrenko, 2015), however, this cell line grows poorly in soft agar (Li et al., 2008). When SHANK2 was ectopically expressed in 293T cells, significant increased number of colonies formed in soft agar growth assay (Fig. 3C), demonstrating that SHANK2 indeed was able to transform human cells. SHANK2's pro-growth effect likely depends on YAP activity, since YAP inhibition suppressed such phenotype (Fig. S3C). However due to the potential off-target effect of YAP inhibitor used in this experiment, we cannot rule out other possibilities. Lastly, when 293T cells were engrafted in nude mice, SHANK2 significantly enhanced growth *in vivo* (Figs. 3D and S4A).

In another experiment, we tested whether SHANK2 could promote *in vivo* growth of a mouse mammary cell line Comma-D $\beta$ . Control or SHANK2-expressing cells were transplanted to mammary fat pad to analyze their rate of growth *in vivo*. The results showed that SHANK2 also significantly enhanced tumor growth in this model (Figs. 3E and S4B).

We further asked whether SHANK2 can promote tumor formation by endogenous cells in mice. Using a transposon system (Yant et al., 2004), murine versions of c-Myc and the p53 R246S dominant negative mutant were integrated into genomes of mouse liver cells via hydrodynamic injection. Such a genetic combination resulted in one small liver tumor in three mice. When SHANK2 is also included in the experiment, numerous huge liver tumors were observed in 4 weeks after hydrodynamic injection in all three mice, demonstrating that SHANK2 indeed potently promotes cancer formation *in vivo* (Fig. 3F and 3F').

Importantly, in all three *in vivo* models, SHANK2-overexpressing tumors showed increased CTGF and CYR61 levels (Figs. 3F'', S4C, and S4D), indicating enhanced YAP activity. In addition, immunostaining of the liver model showed that SHANK2 promotes YAP nuclear retention *in vivo* (Fig. S4E).

Lastly, we examined potential correlation between SHANK2 and CTGF, CYR61 expression levels. Analysis of uterine corpus endometrial carcinoma and esophageal carcinoma, two cancer types with the most prominent SHANK2





◀ **Figure 4. SHANK2 deregulates Hippo pathway by antagonizing LATS1 activity through sequestration of ARHGEF7.** (A) Co-immunoprecipitation of ARHGEF7 and LATS1. (B) Co-immunoprecipitation of ARHGEF7 and SHANK2. (C and C') SHANK2 overexpression reduced ARHGEF7-LATS1 interaction. For data shown in (A) to (C), Myc-MCL1 was used as negative control and the experiments were done in 293T cells. The relative amount of ARHGEF7-LATS1 interactions were quantitated in (C') as mean  $\pm$  SEM from results of three independent experiments. *P* value was calculated by Student's *t* test; \*\**P* < 0.01. (D and D'') The PDZ domain of SHANK2 mediated SHANK2-ARHGEF7 interaction and was crucial for SHANK2's ability to disrupt ARHGEF7-LATS1 interaction. A schematic representation of SHANK protein domains was shown in (D). Deletion of PDZ domain (SHANK2  $\Delta$ PDZ) rendered SHANK2 unable to bind ARHGEF7 and abolished SHANK2's ability to disrupt ARHGEF7-LATS1 interaction (D'). The relative amount of ARHGEF7-LATS1 interactions were quantitated in (D'') as mean  $\pm$  SEM from results of three independent experiments. *P* value was calculated by Student's *t* test; \**P* < 0.05, \*\**P* < 0.01. (E and F) Deletion of PDZ domain rendered SHANK2 unable to reduce YAP phosphorylation (E) or promote YAP nuclear localization (F) in high cell density. Experiments were done in 293T cells. Scale bars: 10  $\mu$ m. (G) CTGF and CYR61 expression level in control, SHANK2 and SHANK2  $\Delta$ PDZ groups. Experiments were done in 293T cells. Data represent mean  $\pm$  SEM from results of three independent experiments. *P* value was calculated by Student's *t* test; \*\*\**P* < 0.001. (H) Deletion of PDZ domain abolished SHANK2's ability to promote liver cancer formation *in vivo*. Vector control or SHANK2,  $\Delta$ PDZ SHANK2 combined with p53R246S and Myc were hydrodynamically injecting into mouse tail vein to induce liver cancer.

overexpression, showed that expression of SHANK2 positively correlates with CTGF and CYR61 (Fig. 3G). The degree of correlation is close to YAP-CTGF/CYR61 correlation. We also examined two established positive regulators of YAP, WBP2 (Lim et al., 2016) and STK26 (Sansores-Garcia et al., 2013) and found the degree of correlation between these two genes and CTGF/CYR61 is also close to SHANK2-CTGF/CYR61 correlation (Fig. S4F). Such correlations provide further support to our hypothesis that SHANK2 positively regulates YAP in cancer. Taken together,

our results strongly support SHANK2's role as a novel oncogene that deregulates Hippo pathway.

### SHANK2 interferes with Hippo signaling through sequestration of ARHGEF7

Next, we investigated the mechanism by which SHANK2 deregulates Hippo signaling. It is known that YAP is phosphorylated and inactivated by LATS1/2. SHANK2 is an actin-associated scaffold protein primarily expressed in nervous system (Naisbitt et al., 1999). Previous study reported that SHANK2 interacts with  $\beta$ -PIX/ARHGEF7 at synapses in cultured neurons (Park et al., 2003). Interestingly, it was recently shown that ARHGEF7 interacts with LATS1 and YAP, and functions as a platform for LATS1-mediated YAP phosphorylation (Heidary Arash et al., 2014). Based on these two studies, we hypothesized that in cancer cells, overexpressed SHANK2 interacts with and sequesters ARHGEF7 away from LATS1, which then leads to reduced LATS1 activity and enhanced cell growth.

Through Co-immunoprecipitation assays, we confirmed that both LATS1 and SHANK2 interact with ARHGEF7 (Fig. 4A and 4B). Importantly, upon SHANK2 overexpression, significantly less amount of ARHGEF7 interacts with LATS1 (Fig. 4C and 4C') and YAP (Fig. S5). Therefore, overexpressed SHANK2 is indeed capable of sequestering ARHGEF7 from LATS1 and YAP.

Of note, the *Drosophila* ortholog gene of ARHGEF7, *Pix*, has been shown to activate *Hpo* kinase, the homologous of MST (Dent et al., 2015). This, and the ARHGEF7-LATS1 interaction in mammalian cells (Heidary Arash et al., 2014) (Fig. 4A) suggest that ARHGEF7/*Pix* functionally interacts with the Hippo pathway core kinases, but the mechanism of regulation may slightly diverge between species.

Consistent with previous report (Park et al., 2003), we found the PDZ domain of SHANK2 is crucial for its interaction with ARHGEF7 (Fig. 4D, 4D', and 4D''). Importantly,  $\Delta$ PDZ SHANK2 could not interfere with ARHGEF7-LATS1 binding (Fig. 4D' and 4D''). Deletion of PDZ from SHANK2 also diminished its ability to deregulate the phosphorylation, localization and activity of YAP (Fig. 4E–G) and to promote liver cancer formation *in vivo* (Fig. 4H). Based on these experimental results, we speculate that overexpressed SHANK2 caused sequestration of ARHGEF7, resulting in




Figure 4. continued.

decreased YAP phosphorylation and deregulated Hippo signaling.

#### Cancer cell lines that overexpress SHANK2 are dependent on SHANK2 for growth


Lastly, we examined cancer cell lines that overexpress SHANK2 and exhibit deregulated Hippo signaling. We asked whether knockdown of SHANK2 could restore Hippo signaling in these cell lines and reduce their proliferation. In multiple human cancer cell lines that overexpress SHANK2, upon SHANK2 knockdown, YAP phosphorylation was restored at high cell density, and YAP were sequestered in cytoplasm under such conditions (Fig. 5A and 5B). This indicated that SHANK2 knockdown restored Hippo signaling in such cells. Moreover, knockdown of SHANK2 resulted in significantly reduced cell number in these cell lines (Fig. 6A). Live cell imaging of these cells indicated that upon SHANK2 knockdown, cellular proliferation was significantly suppressed (Fig. 6B). A small number of cells also underwent cell death over time (Fig. 6B). In contrast, SHANK2 shRNA had little effect on the proliferation of Hippo-proficient cell lines (Fig. 6C). When injected into nude mice, SHANK2 depletion also severely reduced the ability to form tumor *in vivo* (Fig. 6D). In many cases, after SHANK2 depletion no

cancer cell mass was discovered *in vivo*. These data further supported SHANK2's role in Hippo signaling, and suggested SHANK2 may provide a potential target for treating cancer.

#### SHANK2 is prominently amplified in human cancer

To further understand the relative significance of SHANK2 amplification in human cancer, we referenced the COSMIC (Catalogue Of Somatic Mutations In Cancer) database, which provided gene amplification information of approximately 15,000 cancer samples. Interestingly, judging by the number of cancer samples carrying gene amplification, SHANK2 was more frequently amplified than many well-established oncogenes (Fig. 7A).

To more clearly estimate the significance of SHANK2 amplification in human cancer, we compiled gene amplification status for all human coding genes based on the COSMIC dataset. In human cancer, Myc is the most frequently amplified gene. Many genes that are neighboring Myc on chromosome 8q are also significantly co-amplified in cancers. Strikingly, out of the 100 most frequently amplified genes in human cancer, SHANK2 is the only exception that does not reside on chromosome 8q (Fig. 7B, and Table S2). Such a striking amplification status for SHANK2 suggests that it's a very prominent genomic event for human cancer.




**Figure 5. Restoration of Hippo signaling upon depletion of SHANK2.** (A) In Hippo-deficient cancer cell lines Huh1 and Huh7, shRNA-mediated knockdown of SHANK2 restored YAP phosphorylation at high cell density. (B) Knockdown of SHANK2 caused cytoplasm retention of YAP at high cell density in Hippo-deficient cancer cell lines. Scale bars: 35  $\mu$ m.

Since SHANK2's ortholog *Prosap* promotes tissue overgrowth in *Drosophila*, such genomic data suggest that SHANK2 may function as an important oncogene. To our knowledge, so far no studies have shown SHANK2 promotes cancer formation.

SHANK2 is located at the 11q13 tumor amplicon, a relatively large amplicon containing several focal amplification peaks. Cyclin D1, which drives cell cycle progression, is also located in one of such amplification peaks. The TCGA copy number portal database showed Cyclin D1 is located in an

amplification peak that only contains Cyclin D1 and ORAOV1. This suggests that during cancer formation, SHANK2 is selected independent of Cyclin D1.

To further understand this, we performed a detailed analysis of the SHANK2 and Cyclin D1 amplification status in COSMIC tumor samples. There appears to be separate amplification peaks involving SHANK2 and Cyclin D1 (Fig. 7C). Among the 11q13-amplified cancer samples that carry amplification of SHANK2 and/or Cyclin D1, 233 amplified both SHANK2 and Cyclin D1, 412 amplified only



◀ **Figure 6. SHANK2 knockdown inhibits growth of SHANK2 high-expressing cell lines.** (A) SHANK2 shRNA resulted in reduced cell number of Huh1, Huh7 and MDA-MB-468, three cancer cell lines that showed high expression of SHANK2 and defective Hippo signaling. Cells were plated at  $0.5 \times 10^5$  cells/plate and counted each day. Data represent mean  $\pm$  SEM from results of three independent experiments. *P* value was calculated by Student's *t* test; \*\*\**P* < 0.001. (B) The impact of SHANK2 knockdown on cell proliferation and cell death. Real-time imaging was performed for Huh1, Huh7 and MDA-MB-468 that express control vector or SHANK2 shRNA. From each video, three different areas containing  $\sim$ 100 cells were counted for cell division and cell death events during 48 h. Scale bars: 200  $\mu$ m. In the left panel, data represent mean  $\pm$  SEM. *P* value was calculated by Student's *t* test; \*\*\*\**P* < 0.0001. (C) SHANK2 shRNA had minimal effects on cellular proliferation in 293T and SNU449, which express low levels of SHANK2. Cells were plated at  $0.5 \times 10^5$  cells/plate and counted every other day. Data represent mean  $\pm$  SEM from results of three independent experiments. *P* value was calculated by Student's *t* test. ns, not significant. (D) SHANK2 knockdown suppressed tumor growth *in vivo*. 2 million of Huh7 cells expressing vector control or SHANK2 shRNA were transplanted into nude mice, and tumor volume and weight were analyzed at day 27 post injection. Data represent mean  $\pm$  SEM; *n* = 5. *P* value was calculated by Student's *t* test; \*\*\**P* < 0.001.

SHANK2 and 50 amplified only Cyclin D1 (Fig. 7C and Table S3). This suggests that there are separate selective pressures for SHANK2 and Cyclin D1 amplification, and they may both promote cancer. Importantly, in addition to amplification, SHANK2 is also overexpressed in multiple types of human cancer (Fig. 7D) (Tang et al., 2017). A recent study of esophageal squamous cell carcinoma from South Africa also confirmed SHANK2 overexpression via immunohistochemistry staining (Brown et al., 2020). In their analysis, focal amplification of 11q13.3 was observed in 37% of cancer


samples and 79% of these samples showed overexpression of SHANK2. Together with our experimental data, this further strengthens a role for SHANK2 in promoting cancer. Given that in human cancer, SHANK2 is the most frequently amplified gene outside of the Myc amplicon, it may provide explanation for how a significant portion of human cancer disables Hippo signaling and evades contact inhibition.

## DISCUSSION

In this report, we present multiple lines of evidence supporting SHANK2's potential role as a novel oncogene that affects Hippo signaling. Genetically, overexpression of SHANK2's ortholog *Prosap* deregulates Hippo signaling and promotes tissue overgrowth in *Drosophila*. Genomically, SHANK2 is the most frequently amplified gene outside the Myc amplicon in human cancer. Both our analysis of the COSMIC dataset (Fig. 1C) and the Broad cancer gene copy number analysis (Table S1) of the 11q13 tumor amplicon clearly indicates a selection for SHANK2 amplification. Biochemically, SHANK2 regulates Hippo signaling, and its overexpression leads to YAP activation and cellular transformation. Taken together, these results indicate SHANK2 is an evolutionarily conserved regulator of Hippo signaling with oncogenic function in human cancer.

In the Hippo pathway, SHANK2 functions as an upstream regulator. In both *Drosophila* and human cells, depletion or inhibition of YAP/*yki* blocked the pro-growth effect of SHANK2 (Fig. S1F, S1G, and S3C). Given that many cancers amplify SHANK2, this finding may help understand how cancer cells managed to escape from contact inhibition. Our results, and the recent finding that cancerous SWI/SNF mutations cause YAP activation (Chang et al., 2018) will further expand the picture of Hippo pathway's broad involvement in human cancer.

Prior to our study, there were no reports demonstrating SHANK2's oncogenic role in human cancer. Several studies noted SHANK2's amplification in esophageal and oropharyngeal cancer and its association with poor prognosis (Carneiro et al., 2008; Qin et al., 2016; Barros-Filho et al., 2018; Yu et al., 2019; Brown et al., 2020). For example, in a recent analysis of esophageal cancer, a tumor type with frequent 11q13 amplification, SHANK2 overexpression was



◀ **Figure 7. SHANK2 is highly amplified and overexpressed in human cancer.** (A) SHANK2 on 11q13 is one of the most frequently amplified genes in human cancer. Shown are the numbers of tumor samples with amplification of major oncogenes. Data were tallied from COSMIC database. (B) The top 100 most frequently amplified genes in human cancer. Gene amplification status of all human genes were tallied from the COSMIC database and ranked with amplification frequency. Except for SHANK2, all other genes on the top 100 list are on the Myc amplicon at Chromosome 8. (C) Amplification status of 11q13 genes in tumor samples according to COSMIC database. On the Y axis, genes in 11q13 are aligned according to their chromosomal location. On the X axis, each line represents one tumor sample. Tumor samples that amplify both SHANK2 and CCND1 (cyclin D1) are shown in orange. Tumor samples that amplify SHANK2 but not CCND1 are shown in purple. Tumor samples that amplify CCND1 but not SHANK2 are shown in blue. The results indicate there are separate selective pressures for SHANK2 and CCND1 amplification in human cancer. (D) Multiple types of human cancer overexpress SHANK2. Analysis of tumor (red) vs. normal tissue (black) was done base on TCGA dataset. UCEC: uterine corpus endometrial cancer; ESCA: esophageal cancer; CHOL: cholangiocarcinoma; OV: ovarian cancer. \* $P < 0.05$ .


identified as one of the most significant factors for poor patient survival, second only to tumor stage (Qin et al., 2016). These findings further suggest that SHANK2 plays an important role in cancer.

As a novel oncogene, SHANK2 could potentially provide a new target for treating cancer. SHANK2 mutation has been recently linked to autism (Berkel et al., 2010; Won et al., 2012; Schneider et al., 2014), and SHANK2 expression is mostly restricted to the nervous system (Naisbitt et al., 1999; Hayashi et al., 2009; Berkel et al., 2010; Won et al., 2012; Schneider et al., 2014). Immunoblot analysis of various mouse tissues confirmed the lack of expression of SHANK2 in most non-neuron tissues, including bone marrow and

intestine, two major sites of toxicities for cancer treatment (Fig. 8A). Querying of public databases (Pontén et al., 2011; Wu et al., 2016) suggests the expression pattern of SHANK2 in human is similar to mouse, and protein expression of SHANK2 is mainly observed in brain and spinal cord (Fig. 8B and 8C).

Consistent with such expression pattern, full-body SHANK2 knockout mice showed expected neuronal phenotypes and smaller body size but were otherwise normal (Schmeisser et al., 2012; Won et al., 2012). Although low level of SHANK2 expression was observed in mouse liver (Fig. 8), no liver-associated phenotypes were reported for the SHANK2 knockout mice, suggesting that SHANK2 may not be needed for liver function under physiological conditions. Whether SHANK2 is needed in liver under pathological conditions (regeneration after resection and liver damage) remains to be tested in such mice.

Considering the expression pattern of SHANK2 and the knockout mice phenotype, it is possible that SHANK2 is necessary for growth only in cancer cells that overexpress SHANK2, and that most human normal adult tissues do not utilize SHANK2 for growth. Therefore, therapies targeting SHANK2 could potentially be achieved with low toxicity. Given that SHANK2 is a scaffold protein (Naisbitt et al., 1999; Hayashi et al., 2009; Berkel et al., 2010; Won et al., 2012; Schneider et al., 2014), chemically inhibiting its function may prove difficult. However, with the recent advances in siRNA and antisense oligos therapies (Stein and Castanotto, 2017; Setten et al., 2019), it is possible to suppress SHANK2 with these approaches. Vehicles that spare the nervous system could be utilized to limit the side effects of such SHANK2-targeting siRNA and antisense oligos. Alternatively, targeted protein degradation techniques (Gadd et al., 2017) can be utilized. It may be possible to generate PROTACs (proteolysis targeting chimeric molecules) that target SHANK2 for degradation, but do not pass the blood brain barrier. Such drugs could be useful in treating cancers that depend on SHANK2. Given the recent finding that 11q13 amplification does not sensitize cancers to CDK4/6 inhibitor



**Figure 8. SHANK2 expression is mostly restricted to the neuronal system.** (A) SHANK2 expression in adult mice tissues determined by Western blot. (B) mRNA expression of SHANK2 in normal human tissues from BioGPS. Data was obtained for 76 normal human tissues and compartments hybridized against GeneAtlas U133A. (C) Protein expression of SHANK2 in normal human tissues from HIPED (the Human Integrated Protein Expression Database).

(Li et al., 2018), SHANK2 may present an alternative target for treating cancers with 11q13 amplification.

Among the three mammalian homologs of *Prosap*, SHANK2 is the most prominently amplified gene in human cancer. About five-fold more cancer samples exhibit SHANK2 amplification compared to SHANK1 and SHANK3. The protein domains of these three SHANK genes are very similar (Fig. S6), however due to the big size of these proteins and the difficulty to clone them, we only focused on SHANK2 in this study. We cannot speculate whether SHANK1 and SHANK3 similarly interfere with Hippo signaling. If they do, they may also represent potentially interesting therapy targets, since their expression pattern and knockout mice phenotypes (Hung et al., 2008; Peça et al., 2011; Wang et al., 2011) are similar to those of SHANK2.

With regard to how SHANK2 regulates Hippo signaling, our study points to a possible explanation that SHANK2 disrupts the interaction between LATS1 and ARHGEF7. Interestingly, SHANK2 is an actin cytoskeleton bundling protein, and it is known that actin affects Hippo signaling (Dupont et al., 2011; Yu et al., 2012; Zhao et al., 2012). Therefore, other possibilities as to how SHANK2 affect Hippo pathway also exists. For example, considering SHANK2's interaction with the actin cytoskeleton, its over-expression may also affect cell junctions to alter Hippo signaling. Our data suggests that deletion of PDZ domains from SHANK2 abolished its ability to regulate LATS1/2. It is possible that aside from ARHGEF7, other cell junction

proteins may also interact with the PDZ domain of SHANK2 and contribute to such phenotype. This remains a question for further research.

Of note, the molecular events from actin to Hippo signaling remain a subject of study, our study of the SHANK2-ARHGEF7-LATS1 interactions provided such a possible route. Considering that in human SHANK2 is not expressed in most adult tissues, such a mechanism may be more relevant to pathological conditions, when SHANK2 is amplified in cancers. On the other hand, knocking down of SHANK2 in several cell lines led to severe block of cell growth (Fig. 6A). It is possible that mechanisms other than LATS1/2 inhibition also contributed to such a dramatic phenotype.

Taken together, our study for the first time assigned an oncogenic function for SHANK2, one of the most prominently amplified genes in human cancer. Our results indicate that SHANK2 is an evolutionarily conserved regulator of Hippo signaling. This study provides further insight into how cancer cells deregulate Hippo signaling and evade contact inhibition, and points to a potential intervention target for cancer therapy.

#### ACKNOWLEDGEMENTS

This work was supported by the major scientific research project (Grant Nos. 2017YFA0504503, 2019YFA0802001 and 2017YFA0103601), the National Natural Science Foundation of China (Grant Nos. 81972600, 31530043 and 31625017), the Strategic Priority Research Program of Chinese Academy of



Sciences, Grant No. XDB19000000, and Shanghai Leading Talents Program to L.Z. We thank Dr. Faxing Yu for helpful discussions on the project, and Dr. Xin Chen and Dr. Jianming Chen for kindly providing reagents and fly strains. We thank the technical help from Animal Core Facility and Core Facility for Cell Biology at SIBCB.

## AUTHOR CONTRIBUTIONS

HJ conceived the project. HJ, LZ and YAZ. designed the experiments. LX conducted most of the experiment in mammalian cells and cancer data analysis. PXL performed the screen in *Drosophila* with help from XH and YL. WQS conducted the mouse mammary tumor formation experiment. JY and LS participated in the mouse liver tumor formation experiment. MXL, HYD, SSC and ALY participated in COSMIC data analysis. HJ and LX analyzed the data and wrote the paper. All authors discussed the results and commented on the manuscript. HJ supervised the study.

## ABBREVIATIONS

CCND1, cyclin D1; CHOL, cholangiocarcinoma; COSMIC, Catalogue Of Somatic Mutations In Cancer; ECM, extracellular matrix; ESCA, esophageal cancer; HD, high cell density; HIPED, the Human Integrated Protein Expression Database; LD, low cell density; OV, ovarian cancer; PFA, paraformaldehyde; qPCR, quantitative polymerase chain reaction; SHANK2, SH3 and multiple ankyrin repeat domains 2; UCEC, uterine corpus endometrial carcinoma; TCGA, the cancer genome atlas

## COMPLIANCE WITH ETHICS GUIDELINES

Liang Xu, Peixue Li, Xue Hao, Yi Lu, Mingxian Liu, Wenqian Song, Lin Shan, Jiao Yu, Hongyu Ding, Shishuang Chen, Ailing Yang, Yi Arial Zeng, Lei Zhang and Hai Jiang declare that they have no conflict of interest. All institutional and national guidelines for the care and use of laboratory animals were followed.

## COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

## OPEN ACCESS

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from

the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## REFERENCES

- Atkins M, Potier D, Romanelli L, Jacobs J, Mach J, Hamaratoglu F, Aerts S, Halder G (2016) An ectopic network of transcription factors regulated by hippo signaling drives growth and invasion of a malignant tumor model. *Curr Biol* 26(16):2101–2113
- Barros-Filho MC, Reis-Rosa LA, Hatakeyama M, Marchi FA, Chulam T, Scapulatempo-Neto C, Nicolau UR, Carvalho AL, Pinto CAL, Drigo SA et al (2018) Oncogenic drivers in 11q13 associated with prognosis and response to therapy in advanced oropharyngeal carcinomas. *Oral Oncol* 83:81–90
- Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, Endris V, Roberts W, Szatmari P, Pinto D et al (2010) Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. *Nat Genet* 42(6):489–491
- Brown J, Stepien AJ, Willem P (2020) Landscape of copy number aberrations in esophageal squamous cell carcinoma from a high endemic region of South Africa. *BMC Cancer* 20(1):281
- Carneiro A, Isinger A, Karlsson A, Johansson J, Jönsson G, Bendahl PO, Falkenback D, Halvarsson B, Nilbert M (2008) Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. *BMC Cancer* 8:98
- Chakraborty S, Njah K, Pobbati AV, Lim YB, Raju A, Lakshmanan M, Tergaonkar V, Lim CT, Hong W (2017) Agrin as a mechanotransduction signal regulating YAP through the Hippo pathway. *Cell Rep* 18(10):2464–2479
- Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, Lucon Xiccato R, Aragona M, Giulitti S, Panciera T, Gandin A et al (2018) The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. *Nature* 563(7730):265–269
- Dent LG, Poon CLC, Zhang X, Degoutin JL, Tipping M, Veraksa A, Harvey KF (2015) The GTPase regulatory proteins pix and git control tissue growth via the hippo pathway. *Curr Biol* 25(1):124–130
- Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in drosophila and mammals. *Cell* 130(6):1120–1133
- Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S et al (2011) Role of YAP/TAZ in mechanotransduction. *Nature* 474(7350):179–183
- Engels WR (1996) P elements in *Drosophila*. *Curr Top Microbiol Immunol* 204:103–123
- Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A et al (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry. *Cancer Cell* 25(6):831–845
- Fernandez-L A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM (2009) YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and

- mediates Sonic hedgehog-driven neural precursor proliferation. *Genes Dev* 23(23):2729–2741
- Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, Zengerle M, Ciulli A (2017) Structural basis of PROTAC cooperative recognition for selective protein degradation. *Nat Chem Biol* 13(5):514–521
- Gumbiner BM, Kim NG (2014) The Hippo-YAP signaling pathway and contact inhibition of growth. *J Cell Sci* 127(Pt 4):709–717
- Guo T, Lu Y, Li P, Yin MX, Lv D, Zhang W, Wang H, Zhou Z, Ji H, Zhao Y et al (2013) A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity. *Cell Res* 23(10):1201–1214
- Halder G, Johnson RL (2011) Hippo signaling: growth control and beyond. *Development* 138(1):9–22
- Halder G, Dupont S, Piccolo S (2012) Transduction of mechanical and cytoskeletal cues by YAP and TAZ. *Nat Rev Mol Cell Biol* 13(9):591–600
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144(5):646–674
- Harvey KF, Pflieger CM, Hariharan IK (2003) The *Drosophila* Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. *Cell* 114(4):457–467
- Hayashi MK, Tang C, Verpelli C, Narayanan R, Stearns MH, Xu RM, Li H, Sala C, Hayashi Y (2009) The postsynaptic density proteins Homer and Shank form a polymeric network structure. *Cell* 137(1):159–171
- Heidary Arash E, Song KM, Song S, Shiban A, Attisano L (2014) Arhgef7 promotes activation of the Hippo pathway core kinase Lats. *EMBO J* 33(24):2997–3011
- Hu L, Xu J, Yin MX, Lu Y, Wu W, Xue Z, Ho MS, Gao G, Zhao Y, Zhang L et al (2016) Ack promotes tissue growth via phosphorylation and suppression of the Hippo pathway component Expanded. *Cell Discov* 2:15047
- Huang HL, Wang S, Yin MX, Dong L, Wang C, Wu W, Lu Y, Feng M, Dai C, Guo X et al (2013) Par-1 regulates tissue growth by influencing hippo phosphorylation status and Hippo-Salvador association. *PLoS Biol* 11(8):e1001620
- Huang J, Wu S, Barrera J, Matthews K, Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* homolog of YAP. *Cell* 122(3):421–434
- Hung AY, Futai K, Sala C, Valtschanoff JG, Ryu J, Woodworth MA, Kidd FL, Sung CC, Miyakawa T, Bear MF et al (2008) Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. *J Neurosci* 28(7):1697–1708
- Jia J, Zhang W, Wang B, Trinko R, Jiang J (2003) The *Drosophila* Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. *Genes Dev* 17(20):2514–2519
- Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W et al (2014) A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. *Cancer Cell* 25(2):166–180
- Lee T, Luo L (2001) Mosaic analysis with a repressible cell marker (MARCM) for *Drosophila* neural development. *Trends Neurosci* 24(5):251–254
- Li J, Belogortseva N, Porter D, Park M (2008) Chmp1A functions as a novel tumor suppressor gene in human embryonic kidney and ductal pancreatic tumor cells. *Cell Cycle* 7(18):2886–2893
- Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF et al (2018) Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway. *Cancer Cell* 34(6):893–905
- Lim SK, Lu SY, Kang SA, Tan HJ, Li Z, Wee ZNA, Guan JS, Chichili VPR, Sivaraman J, Putti T et al (2016) Wnt signaling promotes breast cancer by blocking ITCH-mediated degradation of YAP/TAZ transcriptional coactivator WBP2. *Cancer Res* 76(21):6278–6289
- Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W et al (2010) The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF $\beta$ -TrCP E3 ligase. *J Biol Chem* 285(48):37159–37169
- Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L et al (2019) MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. *Br J Cancer* 120(4):387–397
- Malik SA, Khan MS, Dar M, Hussain MU, Shah MA, Shafi SM, Mudassar S (2018) Molecular alterations and expression dynamics of LATS1 and LATS2 genes in non-small-cell lung carcinoma. *Pathol Oncol Res* 24(2):207–214
- Merritt NM, Fullenkamp CA, Hall SL, Qian Q, Desai C, Thomason J, Lambert AM, Dupuy AJ, Darbro B, Tanas MR (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. *Oncotarget* 9(60):31620–31636
- Naisbitt S, Eunjoon K, Tu JC, Xiao B, Sala C, Valtschanoff J, Weinberg RJ, Worley PF, Sheng M (1999) Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. *Neuron* 23(3):569–582
- Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng C-X, Brugge JS, Haber DA (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. *Proc Natl Acad Sci USA* 103(33):12405–12410
- Pantalacci S, Tapon N, Léopold P (2003) The salvador partner Hippo promotes apoptosis and cell-cycle exit in *Drosophila*. *Nat Cell Biol* 5(10):921–927
- Park E, Na M, Choi J, Kim S, Lee JR, Yoon J, Park D, Sheng M, Kim E (2003) The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the  $\beta$ PIX guanine nucleotide exchange factor for Rac1 and Cdc42. *J Biol Chem* 278(21):19220–19229
- Peça J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, Lascola CD, Fu Z, Feng G (2011) Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. *Nature* 472(7344):437–442
- Pontén FK, Schwenk JM, Asplund A, Edqvist PHD (2011) The Human Protein Atlas as a proteomic resource for biomarker discovery. *J Intern Med* 270(5):428–446
- Qin H De, Liao XY, Chen Y Bin, Huang SY, Xue WQ, Li FF, Ge XS, Liu DQ, Cai Q, Long J et al (2016) Genomic characterization of esophageal squamous cell carcinoma reveals critical genes

- underlying tumorigenesis and poor prognosis. *Am J Hum Genet* 98(4):709–727
- Rørth P (1996) A modular misexpression screen in *Drosophila* detecting tissue-specific phenotypes. *Proc Natl Acad Sci USA* 93(22):12418–12422
- Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadou S, Liu DL, Kantheti HS, Saghaforina S et al (2018) Oncogenic signaling pathways in the cancer genome atlas. *Cell* 173(2):321–337
- Sansores-Garcia L, Atkins M, Moya IM, Shahmoradgoli M, Tao C, Mills GB, Halder G (2013) Mask is required for the activity of the hippo pathway effector Yki/YAP. *Curr Biol* 23(3):229–235
- Schmeisser MJ, Ey E, Wegener S, Bockmann J, Stempel AV, Kuebler A, Janssen AL, Udvardi PT, Shibani E, Spilker C et al (2012) Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. *Nature* 486(7402):256–260
- Schneider K, Seemann E, Liebmann L, Ahuja R, Koch D, Westermann M, Hübner CA, Kessels MM, Qualmann B (2014) ProSAP1 and membrane nanodomain-associated syndapin I promote postsynapse formation and function. *J Cell Biol* 205(2):197–215
- Seidel C, Schagdarsurengin U, Blümke K, Würfl P, Pfeifer GP, Hauptmann S, Taubert H, Dammann R (2007) Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. *Mol Carcinog* 46(10):865–871
- Setten RL, Rossi JJ, Han S (2019) The current state and future directions of RNAi-based therapeutics. *Nat Rev Drug Discov* 18(6):421–446
- Siew WC, Chun JL, Guo K, Chee PN, Lee I, Hunziker W, Zeng Q, Hong W (2008) A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. *Cancer Res* 68(8):2592–2598
- Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM et al (2010) Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. *Proc Natl Acad Sci USA* 107(4):1431–1436
- Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y et al (2014) Identification of genomic alterations in oesophageal squamous cell cancer. *Nature* 509(7498):91–95
- Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. *Mol Ther* 25(5):1069–1075
- Stepanenko AA, Dmitrenko VV (2015) HEK293 in cell biology and cancer research: Phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. *Gene* 569(2):182–190
- Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 45(W1):W98–W102
- Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G (2003) Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. *Nat Cell Biol* 5(10):914–920
- Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, Chen J (2015) AMPK modulates Hippo pathway activity to regulate energy homeostasis. *Nat Cell Biol* 17(4):490–499
- Wang X, McCoy PA, Rodriguiz RM, Pan Y, Je HS, Roberts AC, Kim CJ, Berrios J, Colvin JS, Bousquet-Moore D et al (2011) Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. *Hum Mol Genet* 20(15):3093–3108
- Wehr MC, Holder MV, Gailite I, Saunders RE, Maile TM, Ciirdaeva E, Instrell R, Jiang M, Howell M, Rossner MJ et al (2013) Salt-inducible kinases regulate growth through the Hippo signalling pathway in *Drosophila*. *Nat Cell Biol* 15(1):61–71
- Wierzbicki PM, Adrych K, Kartanowicz D, Stanislawowski M, Kowalczyk A, Godlewski J, Skwierz-Bogdanska I, Celinski K, Gach T, Kulig J et al (2013) Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. *World J Gastroenterol* 19(27):4363–4373
- Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, Ha S, Chung C, Jung ES, Cho YS et al (2012) Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. *Nature* 486(7402):261–265
- Wu C, Jin X, Tsueng G, Afrasiabi C, Su AI (2016) BioGPS: Building your own mash-up of gene annotations and expression profiles. *Nucleic Acids Res* 44(D1):D313–D316
- Wu S, Huang J, Dong J, Pan D (2003) Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with Salvador and Warts. *Cell* 114(4):445–456
- Xiao GH, Chernoff J, Testa JR (2003) NF2: The Wizardry of Merlin. *Genes Chromosomes Cancer* 38(4):389–399
- Yang C-C, Graves HK, Moya IM, Tao C, Hamaratoglu F, Gladden AB, Halder G (2015) Differential regulation of the Hippo pathway by adherens junctions and apical-basal cell polarity modules. *Proc Natl Acad Sci USA* 112(6):1785–1790
- Yant SR, Park J, Huang Y, Mikkelsen JG, Kay MA (2004) Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. *Mol Cell Biol* 24(20):9239–9247
- Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D (2013) XSpatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. *Cell* 154(6):1342–1355
- Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H et al (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell* 150(4):780–791
- Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W et al (2014) Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* 25(6):822–830
- Yu FX, Zhao B, Guan KL (2015) Hippo pathway in organ size control, tissue homeostasis, and cancer. *Cell* 163(4):811–828
- Yu T, Bachman J, Lai ZC (2013) Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. *Genetics* 195(3):1193–1196
- Yu Y, Cao J, Wu W, Zhu Q, Tang Y, Zhu C, Dai J, Li Z, Wang J, Xue L et al (2019) Genome-wide copy number variation analysis identified ANO1 as a novel oncogene and prognostic biomarker in esophageal squamous cell cancer. *Carcinogenesis* 40(10):1198–1208
- Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhang CZ, Wala J, Mermel CH et al (2013) Pan-cancer patterns of somatic copy number alteration. *Nat Genet* 45(10):1134–1140
- Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ et al (2006)

- Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. *Cell* 125(7):1253–1267
- Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J (2008) The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. *Dev Cell* 14(3):377–387
- Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. *Dev Cell* 19(1):27–38
- Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, Feng Y, Zheng C, Wang Z et al (2014) VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. *Cell Res* 24(3):331–343
- Zhao B, Li L, Tumaneng K, Wang CY, Guan KL (2010) A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF $\beta$ -TRCP. *Genes Dev* 24(1):72–85
- Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. *Genes Dev* 26(1):54–68
- Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J et al (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. *Cancer Cell* 16(5):425–438